International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people

Charlotte Gimpel, Carsten Bergmann, Detlef Bockenhauer, Luc Breysem, Melissa A. Cadnapaphornchai, Metin Cetiner, Jan Dudley, Francesco Emma, Martin Konrad, Tess Harris, Peter C Harris, Jens König, Max C. Liebau, Matko Marlais, Djalila Mekahli, Alison M. Metcalfe, Jun Oh, Ronald D. Perrone, Manish D. Sinha, Andrea TitieniRoser Torra, Stefanie Weber, Paul J.D. Winyard, Franz Schaefer

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

These recommendations were systematically developed on behalf of the Network for Early Onset Cystic Kidney Disease (NEOCYST) by an international group of experts in autosomal dominant polycystic kidney disease (ADPKD) from paediatric and adult nephrology, human genetics, paediatric radiology and ethics specialties together with patient representatives. They have been endorsed by the International Pediatric Nephrology Association (IPNA) and the European Society of Paediatric Nephrology (ESPN). For asymptomatic minors at risk of ADPKD, ongoing surveillance (repeated screening for treatable disease manifestations without diagnostic testing) or immediate diagnostic screening are equally valid clinical approaches. Ultrasonography is the current radiological method of choice for screening. Sonographic detection of one or more cysts in an at-risk child is highly suggestive of ADPKD, but a negative scan cannot rule out ADPKD in childhood. Genetic testing is recommended for infants with very-early-onset symptomatic disease and for children with a negative family history and progressive disease. Children with a positive family history and either confirmed or unknown disease status should be monitored for hypertension (preferably by ambulatory blood pressure monitoring) and albuminuria. Currently, vasopressin antagonists should not be offered routinely but off-label use can be considered in selected children. No consensus was reached on the use of statins, but mTOR inhibitors and somatostatin analogues are not recommended. Children with ADPKD should be strongly encouraged to achieve the low dietary salt intake that is recommended for all children.

Original languageEnglish (US)
JournalNature Reviews Nephrology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Autosomal Dominant Polycystic Kidney
Consensus
Nephrology
Pediatrics
Cystic Kidney Diseases
Off-Label Use
Minors
Patient Advocacy
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Ambulatory Blood Pressure Monitoring
Albuminuria
Medical Genetics
Genetic Testing
Somatostatin
Radiology
Ethics
Cysts
Ultrasonography
Salts
Hypertension

ASJC Scopus subject areas

  • Nephrology

Cite this

International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. / Gimpel, Charlotte; Bergmann, Carsten; Bockenhauer, Detlef; Breysem, Luc; Cadnapaphornchai, Melissa A.; Cetiner, Metin; Dudley, Jan; Emma, Francesco; Konrad, Martin; Harris, Tess; Harris, Peter C; König, Jens; Liebau, Max C.; Marlais, Matko; Mekahli, Djalila; Metcalfe, Alison M.; Oh, Jun; Perrone, Ronald D.; Sinha, Manish D.; Titieni, Andrea; Torra, Roser; Weber, Stefanie; Winyard, Paul J.D.; Schaefer, Franz.

In: Nature Reviews Nephrology, 01.01.2019.

Research output: Contribution to journalReview article

Gimpel, C, Bergmann, C, Bockenhauer, D, Breysem, L, Cadnapaphornchai, MA, Cetiner, M, Dudley, J, Emma, F, Konrad, M, Harris, T, Harris, PC, König, J, Liebau, MC, Marlais, M, Mekahli, D, Metcalfe, AM, Oh, J, Perrone, RD, Sinha, MD, Titieni, A, Torra, R, Weber, S, Winyard, PJD & Schaefer, F 2019, 'International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people', Nature Reviews Nephrology. https://doi.org/10.1038/s41581-019-0155-2
Gimpel, Charlotte ; Bergmann, Carsten ; Bockenhauer, Detlef ; Breysem, Luc ; Cadnapaphornchai, Melissa A. ; Cetiner, Metin ; Dudley, Jan ; Emma, Francesco ; Konrad, Martin ; Harris, Tess ; Harris, Peter C ; König, Jens ; Liebau, Max C. ; Marlais, Matko ; Mekahli, Djalila ; Metcalfe, Alison M. ; Oh, Jun ; Perrone, Ronald D. ; Sinha, Manish D. ; Titieni, Andrea ; Torra, Roser ; Weber, Stefanie ; Winyard, Paul J.D. ; Schaefer, Franz. / International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. In: Nature Reviews Nephrology. 2019.
@article{08b80ccfaf014ffcac811fb9a4491ea8,
title = "International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people",
abstract = "These recommendations were systematically developed on behalf of the Network for Early Onset Cystic Kidney Disease (NEOCYST) by an international group of experts in autosomal dominant polycystic kidney disease (ADPKD) from paediatric and adult nephrology, human genetics, paediatric radiology and ethics specialties together with patient representatives. They have been endorsed by the International Pediatric Nephrology Association (IPNA) and the European Society of Paediatric Nephrology (ESPN). For asymptomatic minors at risk of ADPKD, ongoing surveillance (repeated screening for treatable disease manifestations without diagnostic testing) or immediate diagnostic screening are equally valid clinical approaches. Ultrasonography is the current radiological method of choice for screening. Sonographic detection of one or more cysts in an at-risk child is highly suggestive of ADPKD, but a negative scan cannot rule out ADPKD in childhood. Genetic testing is recommended for infants with very-early-onset symptomatic disease and for children with a negative family history and progressive disease. Children with a positive family history and either confirmed or unknown disease status should be monitored for hypertension (preferably by ambulatory blood pressure monitoring) and albuminuria. Currently, vasopressin antagonists should not be offered routinely but off-label use can be considered in selected children. No consensus was reached on the use of statins, but mTOR inhibitors and somatostatin analogues are not recommended. Children with ADPKD should be strongly encouraged to achieve the low dietary salt intake that is recommended for all children.",
author = "Charlotte Gimpel and Carsten Bergmann and Detlef Bockenhauer and Luc Breysem and Cadnapaphornchai, {Melissa A.} and Metin Cetiner and Jan Dudley and Francesco Emma and Martin Konrad and Tess Harris and Harris, {Peter C} and Jens K{\"o}nig and Liebau, {Max C.} and Matko Marlais and Djalila Mekahli and Metcalfe, {Alison M.} and Jun Oh and Perrone, {Ronald D.} and Sinha, {Manish D.} and Andrea Titieni and Roser Torra and Stefanie Weber and Winyard, {Paul J.D.} and Franz Schaefer",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41581-019-0155-2",
language = "English (US)",
journal = "Nature Reviews Nephrology",
issn = "1759-507X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people

AU - Gimpel, Charlotte

AU - Bergmann, Carsten

AU - Bockenhauer, Detlef

AU - Breysem, Luc

AU - Cadnapaphornchai, Melissa A.

AU - Cetiner, Metin

AU - Dudley, Jan

AU - Emma, Francesco

AU - Konrad, Martin

AU - Harris, Tess

AU - Harris, Peter C

AU - König, Jens

AU - Liebau, Max C.

AU - Marlais, Matko

AU - Mekahli, Djalila

AU - Metcalfe, Alison M.

AU - Oh, Jun

AU - Perrone, Ronald D.

AU - Sinha, Manish D.

AU - Titieni, Andrea

AU - Torra, Roser

AU - Weber, Stefanie

AU - Winyard, Paul J.D.

AU - Schaefer, Franz

PY - 2019/1/1

Y1 - 2019/1/1

N2 - These recommendations were systematically developed on behalf of the Network for Early Onset Cystic Kidney Disease (NEOCYST) by an international group of experts in autosomal dominant polycystic kidney disease (ADPKD) from paediatric and adult nephrology, human genetics, paediatric radiology and ethics specialties together with patient representatives. They have been endorsed by the International Pediatric Nephrology Association (IPNA) and the European Society of Paediatric Nephrology (ESPN). For asymptomatic minors at risk of ADPKD, ongoing surveillance (repeated screening for treatable disease manifestations without diagnostic testing) or immediate diagnostic screening are equally valid clinical approaches. Ultrasonography is the current radiological method of choice for screening. Sonographic detection of one or more cysts in an at-risk child is highly suggestive of ADPKD, but a negative scan cannot rule out ADPKD in childhood. Genetic testing is recommended for infants with very-early-onset symptomatic disease and for children with a negative family history and progressive disease. Children with a positive family history and either confirmed or unknown disease status should be monitored for hypertension (preferably by ambulatory blood pressure monitoring) and albuminuria. Currently, vasopressin antagonists should not be offered routinely but off-label use can be considered in selected children. No consensus was reached on the use of statins, but mTOR inhibitors and somatostatin analogues are not recommended. Children with ADPKD should be strongly encouraged to achieve the low dietary salt intake that is recommended for all children.

AB - These recommendations were systematically developed on behalf of the Network for Early Onset Cystic Kidney Disease (NEOCYST) by an international group of experts in autosomal dominant polycystic kidney disease (ADPKD) from paediatric and adult nephrology, human genetics, paediatric radiology and ethics specialties together with patient representatives. They have been endorsed by the International Pediatric Nephrology Association (IPNA) and the European Society of Paediatric Nephrology (ESPN). For asymptomatic minors at risk of ADPKD, ongoing surveillance (repeated screening for treatable disease manifestations without diagnostic testing) or immediate diagnostic screening are equally valid clinical approaches. Ultrasonography is the current radiological method of choice for screening. Sonographic detection of one or more cysts in an at-risk child is highly suggestive of ADPKD, but a negative scan cannot rule out ADPKD in childhood. Genetic testing is recommended for infants with very-early-onset symptomatic disease and for children with a negative family history and progressive disease. Children with a positive family history and either confirmed or unknown disease status should be monitored for hypertension (preferably by ambulatory blood pressure monitoring) and albuminuria. Currently, vasopressin antagonists should not be offered routinely but off-label use can be considered in selected children. No consensus was reached on the use of statins, but mTOR inhibitors and somatostatin analogues are not recommended. Children with ADPKD should be strongly encouraged to achieve the low dietary salt intake that is recommended for all children.

UR - http://www.scopus.com/inward/record.url?scp=85066279632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066279632&partnerID=8YFLogxK

U2 - 10.1038/s41581-019-0155-2

DO - 10.1038/s41581-019-0155-2

M3 - Review article

C2 - 31118499

AN - SCOPUS:85066279632

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-507X

ER -